Cargando…
Fetal liver mesenchymal stem cells restore ovarian function in premature ovarian insufficiency by targeting MT1
BACKGROUND: With the development of regenerative medicine and tissue engineering technology, almost all stem cell therapy is efficacious for the treatment of premature ovarian failure (POF) or premature ovarian insufficiency (POI) animal models, whereas little stem cell therapy has been practiced in...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884777/ https://www.ncbi.nlm.nih.gov/pubmed/31783916 http://dx.doi.org/10.1186/s13287-019-1490-8 |
_version_ | 1783474615878680576 |
---|---|
author | Huang, Boxian Qian, Chunfeng Ding, Chenyue Meng, Qingxia Zou, Qinyan Li, Hong |
author_facet | Huang, Boxian Qian, Chunfeng Ding, Chenyue Meng, Qingxia Zou, Qinyan Li, Hong |
author_sort | Huang, Boxian |
collection | PubMed |
description | BACKGROUND: With the development of regenerative medicine and tissue engineering technology, almost all stem cell therapy is efficacious for the treatment of premature ovarian failure (POF) or premature ovarian insufficiency (POI) animal models, whereas little stem cell therapy has been practiced in clinical settings. The underlying molecular mechanism and safety of stem cell treatment in POI are not fully understood. In this study, we explored whether fetal mesenchymal stem cells (fMSCs) from the liver restore ovarian function and whether melatonin membrane receptor 1 (MT1) acts as a regulator for treating POI disease. METHODS: We designed an in vivo model (chemotherapy-induced ovary damage) and an in vitro model (human ovarian granulosa cells (hGCs)) to understand the efficacy and molecular cues of fMSC treatment of POI. Follicle development was observed by H&E staining. The concentration of sex hormones in serum (E2, AMH, and FSH) and the concentration of oxidative and antioxidative metabolites and the enzymes MDA, SOD, CAT, LDH, GR, and GPx were measured by ELISA. Flow cytometry (FACS) was employed to detect the percentages of ROS and proliferation rates. mRNA and protein expression of antiapoptotic genes (SURVIVIN and BCL2), apoptotic genes (CASPASE-3 and CASPASE-9), and MT1 and its downstream genes (JNK1, PCNA, AMPK) were tested by qPCR and western blotting. MT1 siRNA and related antagonists were used to assess the mechanism. RESULTS: fMSC treatment prevented cyclophosphamide (CTX)-induced follicle loss and recovered sex hormone levels. Additionally, fMSCs significantly decreased oxidative damage, increased oxidative protection, improved antiapoptotic effects, and inhibited apoptotic genes in vivo and in vitro. Furthermore, fMSCs also upregulated MT1, JNK1, PCNA, and AMPK at the mRNA and protein levels. With MT1 knockdown or antagonist treatment in normal hGCs, the protein expression of JNK1, PCNA, and AMPK and the percentage of proliferation were impaired. CONCLUSIONS: fMSCs might play a crucial role in mediating follicular development in the POI mouse model and stimulating the activity of POI hGCs by targeting MT1. |
format | Online Article Text |
id | pubmed-6884777 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-68847772019-12-03 Fetal liver mesenchymal stem cells restore ovarian function in premature ovarian insufficiency by targeting MT1 Huang, Boxian Qian, Chunfeng Ding, Chenyue Meng, Qingxia Zou, Qinyan Li, Hong Stem Cell Res Ther Research BACKGROUND: With the development of regenerative medicine and tissue engineering technology, almost all stem cell therapy is efficacious for the treatment of premature ovarian failure (POF) or premature ovarian insufficiency (POI) animal models, whereas little stem cell therapy has been practiced in clinical settings. The underlying molecular mechanism and safety of stem cell treatment in POI are not fully understood. In this study, we explored whether fetal mesenchymal stem cells (fMSCs) from the liver restore ovarian function and whether melatonin membrane receptor 1 (MT1) acts as a regulator for treating POI disease. METHODS: We designed an in vivo model (chemotherapy-induced ovary damage) and an in vitro model (human ovarian granulosa cells (hGCs)) to understand the efficacy and molecular cues of fMSC treatment of POI. Follicle development was observed by H&E staining. The concentration of sex hormones in serum (E2, AMH, and FSH) and the concentration of oxidative and antioxidative metabolites and the enzymes MDA, SOD, CAT, LDH, GR, and GPx were measured by ELISA. Flow cytometry (FACS) was employed to detect the percentages of ROS and proliferation rates. mRNA and protein expression of antiapoptotic genes (SURVIVIN and BCL2), apoptotic genes (CASPASE-3 and CASPASE-9), and MT1 and its downstream genes (JNK1, PCNA, AMPK) were tested by qPCR and western blotting. MT1 siRNA and related antagonists were used to assess the mechanism. RESULTS: fMSC treatment prevented cyclophosphamide (CTX)-induced follicle loss and recovered sex hormone levels. Additionally, fMSCs significantly decreased oxidative damage, increased oxidative protection, improved antiapoptotic effects, and inhibited apoptotic genes in vivo and in vitro. Furthermore, fMSCs also upregulated MT1, JNK1, PCNA, and AMPK at the mRNA and protein levels. With MT1 knockdown or antagonist treatment in normal hGCs, the protein expression of JNK1, PCNA, and AMPK and the percentage of proliferation were impaired. CONCLUSIONS: fMSCs might play a crucial role in mediating follicular development in the POI mouse model and stimulating the activity of POI hGCs by targeting MT1. BioMed Central 2019-11-29 /pmc/articles/PMC6884777/ /pubmed/31783916 http://dx.doi.org/10.1186/s13287-019-1490-8 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Huang, Boxian Qian, Chunfeng Ding, Chenyue Meng, Qingxia Zou, Qinyan Li, Hong Fetal liver mesenchymal stem cells restore ovarian function in premature ovarian insufficiency by targeting MT1 |
title | Fetal liver mesenchymal stem cells restore ovarian function in premature ovarian insufficiency by targeting MT1 |
title_full | Fetal liver mesenchymal stem cells restore ovarian function in premature ovarian insufficiency by targeting MT1 |
title_fullStr | Fetal liver mesenchymal stem cells restore ovarian function in premature ovarian insufficiency by targeting MT1 |
title_full_unstemmed | Fetal liver mesenchymal stem cells restore ovarian function in premature ovarian insufficiency by targeting MT1 |
title_short | Fetal liver mesenchymal stem cells restore ovarian function in premature ovarian insufficiency by targeting MT1 |
title_sort | fetal liver mesenchymal stem cells restore ovarian function in premature ovarian insufficiency by targeting mt1 |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884777/ https://www.ncbi.nlm.nih.gov/pubmed/31783916 http://dx.doi.org/10.1186/s13287-019-1490-8 |
work_keys_str_mv | AT huangboxian fetallivermesenchymalstemcellsrestoreovarianfunctioninprematureovarianinsufficiencybytargetingmt1 AT qianchunfeng fetallivermesenchymalstemcellsrestoreovarianfunctioninprematureovarianinsufficiencybytargetingmt1 AT dingchenyue fetallivermesenchymalstemcellsrestoreovarianfunctioninprematureovarianinsufficiencybytargetingmt1 AT mengqingxia fetallivermesenchymalstemcellsrestoreovarianfunctioninprematureovarianinsufficiencybytargetingmt1 AT zouqinyan fetallivermesenchymalstemcellsrestoreovarianfunctioninprematureovarianinsufficiencybytargetingmt1 AT lihong fetallivermesenchymalstemcellsrestoreovarianfunctioninprematureovarianinsufficiencybytargetingmt1 |